Preclinical trajectory of AD: Interactions between APOE gene dose & biomarkers
Banner Institute, University of Arizona
Supervising Advisor: Dr. Pierre Tariot
In the current proposal we seek to evaluate neuroimaging data from the longstanding NIA-supported prospective cohort study (RO1 AG031581, Reiman PI) in order to examine the interaction between APOE4 gene dose (greatest genetic risk factor in AD) and measurable Alzheimer’s disease biomarkers such as tau PET imaging and resting-state functional connectivity MRI data. Detection and tracking of biomarkers using brain imaging collected at baseline and at 24-months in late-middle-aged, cognitively unimpaired adults with none, one, or two copies of the APOE4 allele. The overall goal of this initiative is to see how early these biomarkers can be defined, how reliable and valid they are, and then use them ultimately in clinical trials as early biomarkers of likely compound success. Rapid evaluations of preclinical treatments through the establishment of a comprehensive preclinical disease profile database is crucial for development of new preclinical therapies. Results of this work will potentially provide key information to Alzheimer’s prevention initiatives.
This project has continued through the Advisor Fellowships 2016 program